Navigation Links
Sensitivity Enhancements to Monogram's Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy
Date:6/16/2008

, is not only an invaluable part of patient selection for clinical trials, it is also critical to the pre-clinical evaluation of new drug candidates and for optimizing the selection of approved treatments for patient management in routine clinical practice.

About Trofile

Trofile is a clinically validated patient selection tropism assay that determines whether a patient is infected with a strain of HIV that uses either the CCR5 co-receptor (R5), the CXCR4 co-receptor (X4), or a combination of CCR5 and CXCR4 (D/M) to enter cells. The use of CCR5, CXCR4 or both co-receptors defines the "tropism" of the virus strain. Trofile amplifies the entire envelope gene from a patient's HIV genome (from their blood sample) and then uses it to make HIV particles containing the patient's virus envelope protein. The resultant HIV particles are then used to infect cells that contain the CCR5 co-receptor or the CXCR4 co-receptor on the cell surface. Once the virus infects the cell, it undergoes a single round of replication. Virus replication results in the production of luciferase from a luciferase gene that is carried into the cell by the virus. The production of luciferase in either CCR5 cells, CXCR4 cells or both cell types defines the co-receptor tropism of the patient virus. Trofile is the only clinically validated tropism assay and has been used to select patients in all phase II and phase III studies of CCR5 antagonists to date.

About Monogram

Monogram is a biotechnology company advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious infectious diseases and cancer. The Company's products are designed to help doctors optimize treatment regimens for their patients that lead to better outcomes and reduced costs. The Company's technology is also being used by numerous biopharmaceutical companies to develop new and improved antiviral therapeutics and vaccines as well as targe
'/>"/>

SOURCE Monogram Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Agendia Acquires Rights to the Discovery of a Major Drug Resistance Mechanism in Breast Cancer Potentially Leading to a Herceptin(R) Sensitivity Test
2. ANX-514 Reduces Hypersensitivity Reactions Without Impacting Pharmacokinetics or Antitumor Activity in Preclinical Tests
3. Data Presented on Monogram HIV Tropism Tests at Retrovirus Conference sets New Standards of Assay Sensitivity
4. New Dual Cold Probe From Varian, Inc. Increases Sensitivity and Reduces Analysis Times for 13C NMR Experiments
5. Olympus FluoroPoint(TM) System Provides High-Sensitivity Single Molecule and Protein Interaction Analysis for Screening and Research
6. Study Reaffirms Superiority of Trofile(TM) Assay
7. New York Medicaid Program Establishes Coverage for Trofile(TM)
8. Caliper Life Sciences Introduces High Throughput RNA Assay to Improve Workflow in Gene Expression Studies
9. ProImmune Launches New MHC-Peptide Binding Assay for Class II HLA Alleles
10. Assay Designs(TM) Announces Additions to the Leadership Team
11. MedAssets Supply Chain Systems Selects Siemens Medical Solutions Diagnostics for Chemistry, Automation and Immunoassay Solutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014  Organovo announced ... from the National Institutes of Health (NIH) to help ... effective treatments to patients on a faster timeline. Organovo ... Sciences (NCATS) and the National Eye Institute (NEI) to ...
(Date:1/14/2014)... , Jan. 14, 2014  RXi Pharmaceuticals Corporation ... developing and commercializing innovative therapies addressing major unmet ... it received the Notice of Allowance from the ... unique self-delivering RNAi compounds (sd-rxRNA®), for the treatment ...
(Date:1/14/2014)... UK (PRWEB) January 13, 2014 Bob ... with more than 20 years in the industry, has ... photonics . Hainsey will serve as the society’s Science ... Dr. Hainsey join SPIE as our Technology Strategist, further ...
(Date:1/14/2014)... Independent publisher Bitingduck Press, with offices ... has big ideas for 2014 in production and sales ... to produce high-quality, low-cost, DRM-free ebooks and to use ... , The first major development will be bookstore sales ...
Breaking Biology Technology:Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2Bitingduck Press Looks Forward to 2014 With Multimedia E-books 2
... Robert G. Johnson, Jr. Resigns as President and ... Near-Term Commercial Opportunities, HAYWARD, Calif., Feb. 28 ... announced that Robert G. Johnson, Jr.,M.D., Ph.D., has ... a,member of Kosan,s Board of Directors. Helen S. ...
... payment, WILMINGTON, N.C., Feb. 28 PPD, ... Limited,s new drug,application (NDA) for alogliptin, a highly ... diabetes, has been accepted for filing by the ... to develop the,compound., Under PPD,s agreement with ...
... Feb. 28 The Center for Molecular,Medicine (CMM) today ... the,nation to offer a new, FDA-approved test that will ... CMM (http://www.cmmdx.org ) is offering the CellSearch(TM) System ... new tool in managing,patients with metastatic prostate cancer (MPC). ...
Cached Biology Technology:Kosan Announces Senior Management Changes and Clinical Portfolio Priorities 2Kosan Announces Senior Management Changes and Clinical Portfolio Priorities 3Kosan Announces Senior Management Changes and Clinical Portfolio Priorities 4Kosan Announces Senior Management Changes and Clinical Portfolio Priorities 5Kosan Announces Senior Management Changes and Clinical Portfolio Priorities 6Kosan Announces Senior Management Changes and Clinical Portfolio Priorities 7Kosan Announces Senior Management Changes and Clinical Portfolio Priorities 8PPD Confirms Takeda's NDA Filing of Alogliptin with U.S. Food and Drug Administration 2Center for Molecular Medicine Among First to Offer New FDA-Approved Test to Aid in Treatment of Prostate Cancer 2
(Date:4/17/2014)... Several parasites and pathogens that devastate honeybees in Europe, ... Africa, but do not appear to be impacting native ... team of researchers., The invasive pests include including ... East African honeybees appear to be resilient to these ... used to control pests in Europe, Asia and the ...
(Date:4/17/2014)... serious conditions such as heart disease, epilepsy and pain, ... Unfortunately, there is still much scientists do not know ... unexpected insight into the structure of sodium channels and, ... which are responsible for ,fine-tuning, the activity of the ... edition of the Journal of Biological Chemistry . ...
(Date:4/17/2014)... BLOOMINGTON, Ind. -- Indiana University researchers have detected new ... with diabetes. This discovery could have far-reaching implications for ... the care of over 25 million Americans. , "We ... the retinas at such early stages," said Ann Elsner, ... Optometry and lead author of the study. "We set ...
Breaking Biology News(10 mins):East African honeybees are safe from invasive pests… for now 2East African honeybees are safe from invasive pests… for now 3Structure of sodium channels different than previously believed 2New technique detects microscopic diabetes-related eye damage 2New technique detects microscopic diabetes-related eye damage 3
... nature,s repository of chemicals in plants, microbes, and marine ... be a major theme of a five-day scientific conference ... 1,200 natural products researchers from around the world. ... the City University of New York, and other New ...
... Imagine millions of cancer cells organized in thousands of small ... die, you have a candidate for a cancer drug. But ... Opinion on Drug Discovery argues that these 2D models ... effects in the body and may often give researchers misleading ...
... Fla. (July 19, 2012) A study comparing whether endothelial ... from human umbilical cord blood are more proliferative and better ... from human placenta are more vasculogenic., The study, carried out ... in a recent issue of Cell Medicine [2(3)] ...
Cached Biology News:Nature as a source of new medicines subject of ICNPR in NYC 2Nature as a source of new medicines subject of ICNPR in NYC 33-D tumor models improve drug discovery success rate 23-D tumor models improve drug discovery success rate 3Blood vessel forming potential of stem cells from human placenta and umbilical cord blood 2
The imaging screen-K (Kodak), is a 35 x 43 cm storage phosphor screen that is used for the quantitation and imaging of 32P, 33P, 35S, 14C, and 3H....
The filter 695RDF55 Reflect 635 for the Molecular Imager FX is a band pass filter for Cy5 and Alexa Fluor 635 dyes....
... is a 2-color staining method for labeling ... detect apoptotic cells by flow cytometry. The ... for measuring apoptosis in cells, including positive ... performance; washing, reaction and rinsing buffers for ...
The sample holders for gels are used to hold gels in place in the multi-sample tray I, which is used with Molecular Imager FX imaging systems....
Biology Products: